Experienced in Anemia

Roger G. Owen

Leeds, ENG, GB 
Experienced in Anemia
Leeds, ENG, GB 
OverviewLocationsClinical Research

Overview

Roger Owen practices in Leeds, United Kingdom. Mr. Owen is rated as an Experienced expert by MediFind in the treatment of Anemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Schnitzler Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 136 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Leeds, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
Cheltenham, ENG, United Kingdom
Horsham St Faith, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
A Phase II Trial to Investigate the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Enrollment Status: Completed
Publish Date: November 07, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Rituximab
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Enrollment Status: Completed
Publish Date: May 13, 2024
Intervention Type: Drug
Study Drugs: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
Study Phase: Phase 3
View 2 Less Clinical Trials

136 Total Publications

Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic Profiling.
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic Profiling.
Journal: Blood
Published: May 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Owen's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile